Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Buparlisib

Generic Name: Buparlisib

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₁F_₃N_₆O_₂

CAS Number: 944396-07-0

Unique Ingredient Identifier: 0ZM2Z182GD

Overview

Buparlisib has been used in trials studying the treatment and basic science of Lymphoma, Metastases, Lung Cancer, Solid Tumors, and Breast Cancer, among others.

Background

Buparlisib has been used in trials studying the treatment and basic science of Lymphoma, Metastases, Lung Cancer, Solid Tumors, and Breast Cancer, among others.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer

Phase 2

Completed

Posted: 2015/04/01

Sponsor:

University Hospital,...

ID:NCT02404844

Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia

Phase 2

Completed

Posted: 2015/01/19

Sponsor:Canadian Cancer Tria...

ID:NCT02340780

Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma

Phase 2

Terminated

Posted: 2014/11/27

Sponsor:

Anne Chang

ID:NCT02303041

Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)

Phase 2

Completed

Posted: 2014/11/25

Sponsor:Memorial Sloan Kette...

ID:NCT02301364

A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas

Phase 2

Completed

Posted: 2014/08/20

Sponsor:

Patrick Joseph Loehr...

ID:NCT02220855

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Adlai Nortye to Showcase Novel Cancer Immunotherapy and RAS Inhibitor at AACR 2025

a month ago

Adlai Nortye will present findings on two innovative cancer therapies at the AACR Annual Meeting in Chicago this April, highlighting their expanding oncology pipeline.

Adlai Nortye's AN2025 Shows Promise in Head and Neck Cancer Treatment

5 months ago

Adlai Nortye's short interest increased by 28.0% in December, reflecting market activity around the stock.

Adlai Nortye's Buparlisib Poised to Potentially Be First PI3K Inhibitor for Head and Neck Cancer

6 months ago

Adlai Nortye's Buparlisib, a pan-PI3K inhibitor, is in Phase III trials for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) after anti-PD-(L)1 treatment.

Advancing Cancer Treatment: The Promise of Oncolytic Virotherapy Combinations

a year ago

Oncolytic viruses (OVs) selectively replicate within tumor cells, causing direct cell lysis while simultaneously triggering immune responses against cancer, offering a dual mechanism of action against malignancies.

Advances in PARP Inhibitor Combinations Show Promise for Ovarian Cancer Treatment

3 years ago

Recent research demonstrates that combining PARP inhibitors with targeted therapies like ATR inhibitors and WEE1 inhibitors shows potential in overcoming PARP resistance in ovarian cancer patients.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy